Review discusses EGFR-targeted therapies and combinations to improve outcomes in non-small cell lung cancer patients, suggesting novel strategies.
Key Points
The aim is to review recent developments in EGFR-targeted therapies for non-small cell lung cancer, addressing the challenges of resistance and treatment optimization.
Literature search from January 2021 to March 2026 on PubMed and major oncology conferences.
Analysis of TKI combinations with chemotherapy and bispecific antibodies in metastatic non-small cell lung cancer.
Discussion of the role of biomarkers in adapting treatment strategies.
Osimertinib remains standard care, but combined treatments show improved efficacy in high-risk patients with specific mutations.
Biomarker-driven approaches lead to better patient stratification and potential outcomes in therapy effectiveness.
Future strategies will focus on refining predictive biomarkers such as circulating tumor DNA dynamics.